Skip to main content

Lisinopril (Monograph)

Brand names: Prinivil, Zestril
Drug class: Angiotensin-Converting Enzyme Inhibitors
- ACE Inhibitors
VA class: CV800
Chemical name: (S)-1-[N2-[(S-1- Carboxy-3-phenylpropyl]-l-lysyl-l-proline dihydrate
Molecular formula: C21H31N3O5•2H2O
CAS number: 83915-83-7

Medically reviewed by Drugs.com on Oct 26, 2023. Written by ASHP.

Warning

  • May cause fetal and neonatal morbidity and mortality if used during pregnancy.1 2 3 4 74 75 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

  • If pregnancy is detected, discontinue lisinopril as soon as possible.1 2 3 4 75

Introduction

Non-sulfhydryl ACE inhibitor.1 2 3 4 5

Uses for Lisinopril

Hypertension

Management of hypertension (alone or in combination with other classes of antihypertensive agents).1 2 3 4 5

ACE inhibitors are recommended as one of several preferred agents for the initial management of hypertension according to current evidence-based hypertension guidelines; other preferred options include angiotensin II receptor antagonists, calcium-channel blockers, and thiazide diuretics.501 502 503 504 1200 While there may be individual differences with respect to recommendations for initial drug selection and use in specific patient populations, current evidence indicates that these antihypertensive drug classes all generally produce comparable effects on overall mortality and cardiovascular, cerebrovascular, and renal outcomes.501 502 504 1200 1213

Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).501 502 503 504 515 1200 1201

A 2017 ACC/AHA multidisciplinary hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension.1200 (See Table 1.)

Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.

Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).

Table 1. ACC/AHA BP Classification in Adults1200

Category

SBP (mm Hg)

DBP (mm Hg)

Normal

<120

and

<80

Elevated

120–129

and

<80

Hypertension, Stage 1

130–139

or

80–89

Hypertension, Stage 2

≥140

or

≥90

The goal of hypertension management and prevention is to achieve and maintain optimal control of BP.1200 However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.501 503 504 505 506 507 508 515 523 526 530 1200 1201 1207 1209 1222 1223 1229

The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) of <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.1200 In addition, an SBP goal of <130 mm Hg generally is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg.1200 These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.1200 1202 1210

Other hypertension guidelines generally have based target BP goals on age and comorbidities.501 504 536 Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk and have used higher BP thresholds and target BPs in elderly patients501 504 536 compared with those recommended by the 2017 ACC/AHA hypertension guideline.1200

Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the current ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.1222 1223 1224 1229

Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient’s BP treatment goal.1200 1220

For decisions regarding when to initiate drug therapy (BP threshold), the current ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors.1200 1207 ASCVD risk assessment recommended by ACC/AHA for all adults with hypertension.1200

ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).1200

For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommends initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.1200

Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.1200 Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.502 1200

In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP.1200 Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in patients with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.1200

Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to ACE inhibitors.29 53 54 501 504 1200 However, the combination of an ACE inhibitor or an angiotensin II receptor antagonist with a calcium-channel blocker or thiazide diuretic produces similar BP lowering in black patients as in other racial groups.1200

ACE inhibitors may be preferred in hypertensive patients with heart failure, ischemic heart disease, diabetes mellitus, CKD, or cerebrovascular disease or post-MI.501 502 504 523 524 525 526 527 534 535 536 543 1200 1214 1215

Heart Failure

Management of heart failure as adjunctive therapy in patients with inadequate response to diuretics and a cardiac glycoside.1 2 3 4 13 14 15 19 20 524 700

Some evidence indicates that therapy with an ACE inhibitor may be less effective than angiotensin receptor-neprilysin inhibitor (ARNI) therapy (e.g., sacubitril/valsartan) in reducing cardiovascular death and heart failure-related hospitalization.700 702

ACCF, AHA, and the Heart Failure Society of America (HFSA) recommend that patients with chronic symptomatic heart failure and reduced left ventricular ejection fraction (LVEF) (NYHA class II or III) who are able to tolerate an ACE inhibitor or angiotensin II receptor antagonist be switched to therapy containing an ARNI to further reduce morbidity and mortality.700

Mortality Reduction After Acute MI

Used in conjunction with standard therapies (e.g., thrombolytic agents, aspirin, β-adrenergic blocking agents [β-blockers]) to improve survival in hemodynamically stable patients with acute MI.1 2 27

Expert guidelines recommend initiation of an oral ACE inhibitor within the first 24 hours of acute MI in patients with an anterior infarct, heart failure, or ejection fraction ≤40% who do not have any contraindications (e.g., hypotension, shock, renal dysfunction).527 Use with caution (and with gradual upward titration) during initial postinfarction period because of the possibility of hypotension or renal dysfunction.527 1100

Continue therapy indefinitely in patients with left ventricular dysfunction or other compelling indications (e.g., hypertension, diabetes mellitus, CKD).525 1100

Diabetic Nephropathy

A recommended agent in the management of patients with diabetes mellitus and persistent albuminuria† [off-label] who have modestly elevated (30–300 mg/24 hours) or higher (>300 mg/24 hours) levels of urinary albumin excretion; slows rate of progression of renal disease in such patients.62 63 64 65 66 535 536 1232

Lisinopril Dosage and Administration

General

BP Monitoring and Treatment Goals

Administration

Oral Administration

Administer orally once daily without regard to meals.1 2 3 4 Administer as extemporaneously prepared oral suspension in patients unable to swallow tablets.67 69

Reconstitution

Preparation of extemporaneous suspension containing lisinopril 1 mg/mL: Add 10 mL of purified water USP to a polyethylene terephthalate (PET) bottle containing ten 20-mg lisinopril tablets; shake contents for ≥1 minute.1 2 67 69 Add 30 mL of sodium citrate dihydrate (Bicitra) and 160 mL of syrup (Ora-Sweet SF) to the PET bottle; gently shake for several seconds to disperse ingredients.1 2 67 69 Shake suspension before dispensing each dose.1 2 67 69

Dosage

May minimize risk of hypotension in patients currently receiving diuretic therapy by discontinuing the diuretic, reducing diuretic dosage, or cautiously increasing salt intake before initiating lisinopril.600 If diuretic cannot be discontinued, initiate lisinopril in adults at dosage of 5 mg daily under close medical supervision until BP has stabilized.600 (See Hypotension under Cautions and see the individual dosage sections in Dosage and Administration. )

Pediatric Patients

Hypertension
Oral

Children ≥6 years of age: Initially, 0.07 mg/kg (up to 5 mg) once daily.1 2 67 69 1150 Some experts state that dosage may be increased every 2–4 weeks until BP controlled, maximum dosage (0.61 mg/kg or 40 mg daily) reached, or adverse effects occur.1 2 67 69 1150

Adults

Hypertension
Lisinopril Therapy
Oral

Manufacturer recommends initial dosage of 10 mg once daily in patients not receiving a diuretic.600 Adjust dosage based on BP response.600

In patients currently receiving diuretic therapy, discontinue diuretic, if possible, 2–3 days before initiating lisinopril.600 May cautiously resume diuretic therapy if BP not controlled adequately with lisinopril alone.600 If diuretic cannot be discontinued, initiate lisinopril at 5 mg daily under close medical supervision for at least 2 hours and until BP has stabilized for at least an additional hour.600

Usual maintenance dosage: Manufacturer states 20–40 mg once daily.600 Some experts state 10–40 mg once daily.1200

If effectiveness diminishes toward end of dosing interval (particularly likely with daily dosage of 10 mg), consider increasing dosage.600

Lisinopril/Hydrochlorothiazide Fixed-combination Therapy
Oral

Manufacturer states fixed-combination preparation should not be used for initial antihypertensive therapy.3 4

If BP is not adequately controlled by monotherapy with lisinopril or hydrochlorothiazide, can switch to the fixed-combination preparation containing lisinopril 10 mg and hydrochlorothiazide 12.5 mg or, alternatively, lisinopril 20 mg and hydrochlorothiazide 12.5 mg.3 4 Adjust dosage of either or both drugs according to patient’s response; however, dosage of hydrochlorothiazide should not be increased for about 2–3 weeks after initiation of therapy.3 4

Can switch to the fixed-combination preparation if stable dosages of lisinopril or hydrochlorothiazide have been achieved.3

If BP is controlled by monotherapy with hydrochlorothiazide 25 mg daily but potassium loss is problematic, can switch to fixed-combination preparation containing lisinopril 10 mg and hydrochlorothiazide 12.5 mg.3 4

Heart Failure
Oral

Initially, 2.5–5 mg once daily.1 524 Monitor closely (especially patients with SBP <80–100 mg Hg) until BP has stabilized.1 524 To minimize risk of hypotension, reduce diuretic dosage, if possible.1

Initially, 2.5 mg once daily in heart failure patients with hyponatremia (serum sodium concentration <130 mEq/L) under close medical supervision.1 2 600

Usual dosage: 5–40 mg once daily.1 2 13 14

Mortality Reduction After Acute MI
Oral

Manufacturers recommend 5 mg within 24 hours of the onset of MI, followed by 5 mg 24 hours after initial dose, 10 mg 48 hours after initial dose, and then 10 mg daily.1 2 Recommended maintenance dosage: 10 mg daily for 6 weeks.1 2

Other experts recommend 2.5–5 mg daily (initiated within 24 hours after MI) titrated to 10 mg daily or higher.527

If low SBP (≤120 mm Hg) observed when lisinopril therapy is initiated or during the first 3 days post-MI, give lower dose (i.e., 2.5 mg).1 2

If hypotension (SBP <100 mm Hg) occurs, reduce maintenance dosage to 5 mg daily; may temporarily reduce further to 2.5 mg daily if needed.1 2

If prolonged hypotension (SBP <90 mm Hg lasting >1 hour) occurs, discontinue lisinopril.1 2

Prescribing Limits

Pediatric Patients

Hypertension
Oral

Children ≥6 years of age: Maximum 0.61 mg/kg or 40 mg daily.67 69 1150

Adults

Hypertension
Oral

Dosages up to 80 mg daily have been used, but no additional benefit observed.1 2

Dosage of lisinopril/hydrochlorothiazide fixed combination generally should not exceed lisinopril 80 mg and hydrochlorothiazide 50 mg daily.3

Special Populations

Renal Impairment

Hypertension

Initially, 5 mg once daily in adults with Clcr 10–30 mL/minute or 2.5 mg once daily in adults with Clcr <10 mL/minute (usually on hemodialysis).2 Titrate dosage until BP is controlled or to maximum of 40 mg daily.1 2 Manufacturers do not recommend use in hypertensive pediatric patients with Clcr <30 mL/minute per 1.73 m2.67 69

Lisinopril/hydrochlorothiazide fixed combinations are not recommended in patients with severe renal impairment.3

Heart Failure

Initially, 2.5 mg once daily in heart failure patients with moderate to severe renal impairment (Clcr ≤30 mL/minute or Scr >3 mg/dL) under close medical supervision.1 2 600

Mortality Reduction After Acute MI

Use with caution in MI patients with Scr >2 mg/dL.1 2 If renal impairment (Scr >3 mg/dL or a doubling of baseline Scr) occurs during lisinopril therapy, consider discontinuing therapy.1 2

Geriatric Patients

Generally titrate dosage carefully, initiate therapy at the low end of the dosage range.1 2 3

Detailed Lisinopril dosage information

Cautions for Lisinopril

Contraindications

Warnings/Precautions

Warnings

Hypotension

Possible symptomatic hypotension, sometimes associated with oliguria and/or progressive azotemia and, rarely, acute renal failure and/or death.1 2 3 4 Risk of marked hypotension in patients with heart failure with SBP <100 mm Hg, hyponatremia, high-dose or recent intensive diuretic therapy, recent increase in diuretic dose, dialysis, or severe volume and/or salt depletion of any etiology.1 2 600

Potential for excessive hypotension to result in MI or stroke in patients with acute MI1 2 or ischemic cardiovascular or cerebrovascular disease.1 2 3 4 Do not use in patients with acute MI at risk of further serious hemodynamic deterioration following treatment with a vasodilator (e.g., those with SBP ≤100 mm Hg) or in those with cardiogenic shock.1 2

To minimize potential for hypotension, consider recent antihypertensive therapy, extent of BP elevation, sodium intake, fluid status, and other clinical conditions.1 2 May minimize potential for hypotension in patients at risk for excessive hypotension by withholding diuretic therapy (except in patients with heart failure), reducing diuretic dosage, and/or cautiously increasing sodium intake prior to initiation of lisinopril.1 2 600 (See Dosage under Dosage and Administration.)

In patients at risk of excessive hypotension, initiate therapy under close medical supervision; monitor closely for first 2 weeks following initiation of lisinopril or any increase in lisinopril or diuretic dosage.1 2

If excessive hypotension occurs, immediately place patient in a supine position and, if necessary, administer IV infusion of sodium chloride 0.9%.1 2 Transient hypotension is not a contraindication to additional doses; may reinstate therapy cautiously after BP is stabilized (e.g., with volume expansion).1 2 If symptomatic hypotension develops, dosage reduction or discontinuance of lisinopril or diuretic may be necessary.1 2

Hematologic Effects

Neutropenia and agranulocytosis reported with captopril; risk appears to depend principally on presence of renal impairment and/or presence of collagen vascular disease.1 2 3 4 Data insufficient to rule out similar incidence of leukopenia, neutropenia, or agranulocytosis with lisinopril.1 2 3 4 67 69

Consider monitoring leukocyte counts in patients with collagen vascular disease and renal disease.1 2

Hepatic Effects

Clinical syndrome that usually is manifested initially by cholestatic jaundice and may progress to fulminant hepatic necrosis (occasionally fatal) reported rarely with ACE inhibitors.1 2 3 4

If jaundice or marked elevation of liver enzymes occurs, discontinue drug and monitor patient.1 2 3 4

Fetal/Neonatal Morbidity and Mortality

Possible fetal and neonatal morbidity and mortality when used during pregnancy.1 2 3 4 (See Boxed Warning.) Such potential risks occur throughout pregnancy, especially during the second and third trimesters.75

Also may increase the risk of major congenital malformations when administered during the first trimester of pregnancy.74 75

Discontinue as soon as possible when pregnancy is detected, unless continued use is considered lifesaving.75 Nearly all women can be transferred successfully to alternative therapy for the remainder of their pregnancy.76 77

Sensitivity Reactions

Anaphylactoid reactions and/or head and neck angioedema possible; if associated with laryngeal edema, may be fatal.1 2 3 4 67 69 Immediate medical intervention (e.g., epinephrine) for involvement of tongue, glottis, or larynx.1 2 3 4 Antihistamines and corticosteroids may not provide sufficient relief; prolonged observation may be necessary.1 2 3 Use caution in patients with history of angioedema unrelated to ACE inhibitor therapy.1 2 3 4

Intestinal angioedema possible; consider in differential diagnosis of patients who develop abdominal pain.1 2 3 67 69 Manifestations include abdominal pain (with or without nausea or vomiting).1 2 3 67 69 Consider intestinal angioedema in the differential diagnosis of patients receiving ACE inhibitors and presenting with abdominal pain.1 2 3 67 69

Sudden and potentially life-threatening anaphylactoid reactions reported in patients receiving ACE inhibitors while undergoing dialysis with high-flux membranes (e.g., AN69).1 67 69 If anaphylactoid reactions occur, immediately stop dialysis and initiate aggressive therapy (symptoms not relieved by antihistamines).1 67 69 Consider using a different type of dialysis membrane or a different class of antihypertensive agent.1 67 69

Anaphylactoid reactions reported in patients receiving ACE inhibitors while undergoing LDL apheresis with dextran sulfate absorption.1 2 3 4

Life-threatening anaphylactoid reactions reported in at least 2 patients receiving ACE inhibitors while undergoing desensitization treatment with hymenoptera venom.1 2 3 4

Not recommended in patients with a history of angioedema associated with or unrelated to ACE inhibitors.1 2 3 4

General Precautions

Aortic Stenosis/Hypertrophic Cardiomyopathy

Use with caution in patients with obstruction in the outflow tract of the left ventricle (e.g., aortic stenosis, hypertrophic cardiomyopathy).1 2 3 4

Renal Effects

Transient increases in BUN and Scr possible; more likely to occur in patients with preexisting renal impairment or those receiving concomitant diuretic therapy.1 2 3 4 524 Possible increases in BUN and Scr in patients with unilateral or bilateral renal artery stenosis; generally reversible following discontinuance of ACE inhibitor and/or diuretic.1 2 3 4 524

Possible oliguria, progressive azotemia, and, rarely, acute renal failure and/or death in patients with severe heart failure.1 2 3 4

Closely monitor renal function for the first few weeks of therapy in hypertensive patients with unilateral or bilateral renal-artery stenosis.1 2 524 Some patients may require dosage reduction or discontinuance of ACE inhibitor or diuretic.1 2

In patients with acute MI who develop renal impairment (Scr >3 mg/dL or a doubling of baseline Scr), consider discontinuing therapy.1 2

Hyperkalemia

Possible hyperkalemia, especially in patients with renal impairment or diabetes mellitus and those receiving drugs that can increase serum potassium concentration (e.g., potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes).1 2 3 4 524 (See Specific Drugs under Interactions.)

Cough

Persistent and nonproductive cough; resolves after drug discontinuance.1 2 3 4

Surgery/Anesthesia

Hypotension may occur in patients undergoing surgery or during anesthesia with agents that produce hypotension; recommended treatment is fluid volume expansion.600

Use of Fixed Combinations

When used in fixed combination with hydrochlorothiazide, consider the cautions, precautions, and contraindications associated with hydrochlorothiazide.3 4

Specific Populations

Pregnancy

Category C (1st trimester); Category D (2nd and 3rd trimesters).1 2 3 4 (See Fetal/Neonatal Morbidity and Mortality under Cautions and see Boxed Warning.)

Lactation

Distributed into milk in rats; not known whether lisinopril is distributed into milk in humans.1 2 3 4 Discontinue nursing or the drug.1 2 3 4

Pediatric Use

Safety and efficacy not established in children <6 years of age or in those with Clcr <30 mL/minute per 1.73 m2.1 2 67 69

Geriatric Use

Response in patients ≥65 years of age does not appear to differ from that in younger adults; however, use with caution due to greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in the elderly.1 2 3 (See Geriatric Patients under Dosage and Administration and see Special Populations under Pharmacokinetics.)

Renal Impairment

Deterioration of renal function may occur in susceptible patients.1 (See Renal Effects under Cautions.)

Increased lisinopril concentrations, particularly in patients with GFR <30 mL/minute.1 Initial dosage adjustment recommended in patients with severe renal impairment.1 (See Renal Impairment under Dosage and Administration.)

Lisinopril/hydrochlorothiazide fixed combinations are not recommended in patients with severe renal impairment.3

Black Patients

BP reduction may be smaller in black patients compared with nonblack patients.1 2 3 4 29 30 53 54 70 71 (See Hypertension under Uses.)

Higher incidence of angioedema reported with ACE inhibitors in black patients compared with other races.33 54 67 69 1200

Common Adverse Effects

Patients with hypertension: Headache, dizziness, cough, fatigue, diarrhea, upper respiratory tract infection, nausea.1 2 3 4 With fixed combination preparation, muscle cramps, asthenia, orthostatic effects, paresthesia.1 2 3 4

Patients with heart failure: Dizziness, hypotension, headache, diarrhea, chest pain, nausea, abdominal pain, rash, upper respiratory tract infection.1 2

Patients with acute MI: Hypotension, renal dysfunction.1 2

Drug Interactions

Specific Drugs

Drug

Interaction

Comments

Aliskiren

Increased risk of hypotension, syncope, hyperkalemia, and renal impairment (e.g., acute renal failure)600

Monitor BP, renal function, and serum electrolytes closely600

Concomitant use contraindicated in patients with diabetes mellitus; avoid concomitant use in patients with GFR <60 mL/minute per 1.73 m2550 600

Angiotensin II receptor antagonists

Increased risk of hypotension, syncope, hyperkalemia, and renal impairment (e.g., acute renal failure)600

Monitor BP, renal function, and serum electrolytes closely600

Antidiabetic agents

Possible increased hypoglycemic effect, especially during initial weeks of combined treatment and in patients with renal impairment600

Digoxin

Clinically important adverse interactions not observed600

Diuretics

Increased hypotensive effect1 2 3 4

If possible, discontinue diuretic before initiating lisinopril1 2 3 4 (see Dosage under Dosage and Administration)

Diuretics, potassium-sparing (amiloride, spironolactone, triamterene)

Enhanced hyperkalemic effect1 2 3 4

Use with caution; monitor serum potassium concentrations frequently.1 2 3 4 Concomitant therapy generally not recommended in patients with heart failure1 2

Gold compounds (aurothioglucose, gold sodium thiomalate)

Rare nitritoid reactions (facial flushing, nausea, vomiting, hypotension)1 3

Lithium

Increased serum lithium concentrations; possible toxicity1 2 3 4

Monitor serum lithium concentrations frequently1

Nitrates (nitroglycerin)

Clinically important adverse interaction not observed1 2

NSAIAs

Possible decreased antihypertensive response to lisinopril1 2 3 4 (slightly decreased response observed with concomitant indomethacin)1 2

Potential for acute reduction of renal function in patients with impaired renal function1 3 4

Potassium supplements or potassium-containing salt substitutes

Enhanced hyperkalemic effect1

Use with caution; monitor serum potassium concentrations frequently1

Propranolol

Clinically important interaction not observed600
Lisinopril drug interactions (more detail)

Lisinopril Pharmacokinetics

Absorption

Bioavailability

About 25% of oral dose is absorbed.1 2 Absolute bioavailability is about 16% in patients with heart failure.1 2

Peak plasma concentrations achieved within 7 hours; time to reach peak plasma concentrations slightly delayed in patients with acute MI.1 2

Onset

Following a single oral dose, antihypertensive effects are observed within 1 hour, with peak BP reduction at 6 hours.1 2

During chronic therapy, maximum antihypertensive effect is achieved after 2–4 weeks.1 2

Duration

Antihypertensive effect of a single dose persists for about 24 hours; effect at 24 hours substantially smaller than at 6 hours after dosing.1 2

Food

Food does not affect absorption.1 2

Distribution

Extent

Crosses the blood-brain barrier poorly.1 2

Crosses the placenta and is distributed into milk in rats.1 2

Plasma Protein Binding

Not bound to serum proteins other than ACE.1 2

Elimination

Metabolism

Not metabolized.1 2

Elimination Route

Eliminated principally in urine as unchanged drug.1 2

Removed by hemodialysis.1 2

Half-life

12 hours.1 2

Special Populations

In patients with renal impairment (GFR <30 mL/minute), clearance is decreased, plasma concentrations increased; in patients with GFR ≥30 mL/minute, elimination half-life is minimally altered.1 2

In geriatric patients, peak plasma concentrations and AUCs increased (i.e., may be doubled).1 2

Stability

Storage

Oral

Extemporaneous Suspension

1-mg/mL preparation of lisinopril tablets in syrup (Ora-Sweet SF) (see Oral Administration under Dosage and Administration): Stable up to 4 weeks at ≤25°C.1 2 67 69

Tablets

Conventional tablets: 15–30°C.1 2 Protect from moisture, freezing, and excessive heat.1 2

Fixed combination tablets: 15–30°C.3 Protect from excessive light and moisture.3

Actions

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Lisinopril

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

2.5 mg*

Zestril

AstraZeneca

5 mg*

Prinivil

Merck

Zestril

AstraZeneca

10 mg*

Prinivil

Merck

Zestril

AstraZeneca

20 mg*

Prinivil

Merck

Zestril

AstraZeneca

30 mg*

Zestril

AstraZeneca

40 mg*

Zestril

AstraZeneca

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Lisinopril Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

10 mg with Hydrochlorothiazide 12.5 mg*

Prinzide

Merck

Zestoretic

AstraZeneca

20 mg with Hydrochlorothiazide 12.5 mg*

Prinzide

Merck

Zestoretic

AstraZeneca

20 mg with Hydrochlorothiazide 25 mg*

Prinzide

Merck

Zestoretic

AstraZeneca

AHFS DI Essentials™. © Copyright 2024, Selected Revisions November 5, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Merck. Prinivil (lisinopril) tablets prescribing information. Whitehouse Station, NJ; 2006 Mar.

2. AstraZeneca. Zestril (lisinopril) tablets prescribing information. Wilmington, DE: 2005 Jun.

3. Merck. Prinzide (lisinopril and hydrochlorothiazide) tablets prescribing information. Whitehouse Station, NJ; 2004 Nov.

4. AstraZeneca. Zestoretic (lisinopril and hydrochlorothiazide) tablets prescribing information. Wilmington, DE: 2002 Jan.

5. McAreavey D, Robertson JI. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs. 1990; 40:326-345. http://www.ncbi.nlm.nih.gov/pubmed/2226219?dopt=AbstractPlus

6. Squibb. Capoten (captopril) tablets prescribing information. In: Physician’s desk reference. 47th ed. Montvale, NJ: Medical Economics Company Inc; 1993: 2356-62.

7. Reviewer’s comments in Enalaprilat/Enalapril (personal observations).

9. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1984; 26:107-12. http://www.ncbi.nlm.nih.gov/pubmed/6150424?dopt=AbstractPlus

11. US Food and Drug Administration. Dangers of ACE inhibitors during second and third trimesters of pregnancy. FDA Med Bull. 1992; 22:2.

13. Giles TD. Clinical experience with lisinopril in congestive heart failure: focus on the older patient. Drugs. 1990; 39(Suppl. 2):17-22. http://www.ncbi.nlm.nih.gov/pubmed/2160883?dopt=AbstractPlus

14. Giles TD, Katz R, Sullivan JM et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment on congestive heart failure. J Am Coll Cardiol. 1989; 13:1240-7. http://www.ncbi.nlm.nih.gov/pubmed/2539403?dopt=AbstractPlus

15. Lancaster SG, Todd PA. Lisinopril, a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1988;35:646-69.

16. Packer M, Lee WH, Kessler PD. Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. Circulation. 1986; 74:766-74. http://www.ncbi.nlm.nih.gov/pubmed/3019586?dopt=AbstractPlus

17. Packer M, Lee WH, Medina N. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 1987; 106:346-54. http://www.ncbi.nlm.nih.gov/pubmed/3028221?dopt=AbstractPlus

18. Packer M, Lee WH, Yushak M et al. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med. 1986; 315:847-53. http://www.ncbi.nlm.nih.gov/pubmed/3018566?dopt=AbstractPlus

19. Bach R, Zardini P. Long-acting angiotensin-converting enzyme inhibition: once daily lisinopril versus twice daily captopril in mild to moderate heart failure. Am J Cardiol. 1992; 70:70-7C.

20. Zannad F, van den Broek SA, Bory M. Comparison of treatment with lisinopril versus enalapril for congestive heart failure. Am J Cardiol. 1992; 70:78-83C. http://www.ncbi.nlm.nih.gov/pubmed/1377441?dopt=AbstractPlus

21. Oster JR, Materson BL. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med. 1992; 152:704-10. http://www.ncbi.nlm.nih.gov/pubmed/1558426?dopt=AbstractPlus

22. Mason N. Angiotensin-converting enzyme inhibitors and renal function. DICP. 1990; 24:496-505. http://www.ncbi.nlm.nih.gov/pubmed/2188438?dopt=AbstractPlus

23. Baker DW, Konstam MA, Bottorff M. Management of heart failure. JAMA. 1994; 272:1361-6. http://www.ncbi.nlm.nih.gov/pubmed/7933398?dopt=AbstractPlus

24. Young JB. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. Int J Cardiol. 1994; 43:151-63. http://www.ncbi.nlm.nih.gov/pubmed/8181869?dopt=AbstractPlus

25. Sharpe N. ACE inhibitors versus diuretics: when to choose which drug? Cardiovasc Drugs Ther. 1993; 7:877-9. Abstract.

26. Riegger GA. The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure. J Cardiovasc Pharmacol. 1990; 15(Suppl 2):S41-6.

27. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate single and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994; 343:1115-22. http://www.ncbi.nlm.nih.gov/pubmed/7910229?dopt=AbstractPlus

29. Saunders E. Tailoring treatment to minority patients. Am J Med. 1990; 88(Suppl 3B):21-3S. http://www.ncbi.nlm.nih.gov/pubmed/2294761?dopt=AbstractPlus

30. Chrysant SG, Danisa K, Kem DC et al. Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension. 1979; 1:136-41. http://www.ncbi.nlm.nih.gov/pubmed/399939?dopt=AbstractPlus

31. Holland OB, Kuhnert L, Campbell WB et al. Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients. Hypertension. 1983; 5:235-9. http://www.ncbi.nlm.nih.gov/pubmed/6337951?dopt=AbstractPlus

32. Ferguson RK, Vlasses PH, Rotmesch HH. Clinical applications of angiotensin-enzyme inhibitors. Am J Med. 1984; 77:690-8. http://www.ncbi.nlm.nih.gov/pubmed/6091446?dopt=AbstractPlus

33. Hoechst Marion Roussel. Altace (ramipril) capsules prescribing information. Sommerville, NJ; 1995 Jul.

35. Rey E, LeLorier J, Burgess E et al. Report of the Canadian Hypertension Society consensus conference: 3. pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1997; 157:1245-54. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1228354&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/9361646?dopt=AbstractPlus

36. American College of Obstetricians and Gynecologists. ACOG technical bulletin No. 219: hypertension in pregnancy. 1996 Jan.

37. Hanssens M, Keirse MJ, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol. 1991; 78:128-35. http://www.ncbi.nlm.nih.gov/pubmed/2047053?dopt=AbstractPlus

38. Brent Rl, Beckman D. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical teratology counselors. Teratology. 1991; 43:543-6. http://www.ncbi.nlm.nih.gov/pubmed/1882342?dopt=AbstractPlus

39. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol. 1992; 80:429-32. http://www.ncbi.nlm.nih.gov/pubmed/1495700?dopt=AbstractPlus

40. Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med. 1996; 335:257-65. http://www.ncbi.nlm.nih.gov/pubmed/8657243?dopt=AbstractPlus

41. Barr M, Cohen MM. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. Teratology. 1991; 44:485-95. http://www.ncbi.nlm.nih.gov/pubmed/1771591?dopt=AbstractPlus

42. US Food and Drug Administration. Dangers of ACE inhibitors during pregnancy. FDA Med Bull. 1992; 22:2.

43. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9A-38A.

44. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999; 100:2312-8. http://www.ncbi.nlm.nih.gov/pubmed/10587334?dopt=AbstractPlus

45. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341:709-17. http://www.ncbi.nlm.nih.gov/pubmed/10471456?dopt=AbstractPlus

46. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med. 1999; 341:753-4. http://www.ncbi.nlm.nih.gov/pubmed/10471464?dopt=AbstractPlus

47. Anon. Spironolactone for heart failure. Med Lett Drugs Ther. 1999; 41:81-2. http://www.ncbi.nlm.nih.gov/pubmed/10505071?dopt=AbstractPlus

48. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. http://www.ncbi.nlm.nih.gov/pubmed/10818056?dopt=AbstractPlus

49. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. http://www.ncbi.nlm.nih.gov/pubmed/10818055?dopt=AbstractPlus

50. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. http://www.ncbi.nlm.nih.gov/pubmed/10977801?dopt=AbstractPlus

51. Associated Press (American Diabetes Association). Diabetics urged: drop blood pressure. Chicago, IL; 2000 Aug 29. Press Release from web site. http://www.diabetes.org/newsroom/

52. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).

53. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-42. http://www.ncbi.nlm.nih.gov/pubmed/12479770?dopt=AbstractPlus

54. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2022; 288:2981-97.

58. Novartis. Diovan (valsartan) tablets prescribing information. East Hanover, NJ; 2002 Aug.

62. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993; 329:1456-62. http://www.ncbi.nlm.nih.gov/pubmed/8413456?dopt=AbstractPlus

63. Remuzzi G. Slowing the progression of diabetic nephropathy. N Engl J Med. 1993; 329:1496-7. http://www.ncbi.nlm.nih.gov/pubmed/8413463?dopt=AbstractPlus

64. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. http://www.ncbi.nlm.nih.gov/pubmed/8622249?dopt=AbstractPlus

65. Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994; 271:275-9. http://www.ncbi.nlm.nih.gov/pubmed/8295285?dopt=AbstractPlus

66. Fournier A. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1994; 330:937. http://www.ncbi.nlm.nih.gov/pubmed/8114873?dopt=AbstractPlus

67. AstraZeneca. Zestril (lisinopril) tablets prescribing information. Wilmington, DE; 2003 Jul.

69. Merck & Co., Inc. Prinivil (lisinopril) tablets prescribing information. Whitehouse Station, NJ; 2003 Apr.

70. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. http://www.ncbi.nlm.nih.gov/pubmed/15811979?dopt=AbstractPlus

71. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. http://www.ncbi.nlm.nih.gov/pubmed/15811986?dopt=AbstractPlus

72. Leenen FHH, Nwachuku CE, Black HR et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium-channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Hypertension. 2006; 48:374-84. http://www.ncbi.nlm.nih.gov/pubmed/16864749?dopt=AbstractPlus

73. Messerli FH, Staessen JA. Amlodipine better than lisinopril: how one randomized clinical trial ended fallacies from observational studies? Hypertension . 2006; 48:359-61. Editorial..

74. Cooper WO, Hernandez-Diaz S, Arbogast PG et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006; 354:2443-51. http://www.ncbi.nlm.nih.gov/pubmed/16760444?dopt=AbstractPlus

75. Food and Drug Administration. FDA public health advisory: angiotensin-converting enzyme inhibitor (ACE inhibitor) drugs and pregnancy. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053113.htm

76. Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med. 1996; 335:257-65. http://www.ncbi.nlm.nih.gov/pubmed/8657243?dopt=AbstractPlus

77. US Food and Drug Administration. Dangers of ACE inhibitors during pregnancy. FDA Med Bull. 1992; 22:2.

246. Cohn JN. The prevention of heart failure—a new agenda. N Engl J Med. 1992; 327:725-7. http://www.ncbi.nlm.nih.gov/pubmed/1495526?dopt=AbstractPlus

247. Pfeffer MA, Braunwald E, Moyé LA et al for the SAVE Investigators Group. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargment Trial. N Engl J Med. 1992; 327:669-77. http://www.ncbi.nlm.nih.gov/pubmed/1386652?dopt=AbstractPlus

250. Sharpe N, Smith H, Murphy J et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 1991; 337:872-6. http://www.ncbi.nlm.nih.gov/pubmed/1672967?dopt=AbstractPlus

251. Oldroyd KG, Pye MP, Ray SG et al. Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. Am J Cardiol. 1991; 68:713-8. http://www.ncbi.nlm.nih.gov/pubmed/1892076?dopt=AbstractPlus

252. Sharpe N, Murphy J, Smith H et al. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1988; 1:255-9. http://www.ncbi.nlm.nih.gov/pubmed/2893080?dopt=AbstractPlus

253. Pfeffer MA, Lamas GA, Vaughan DE et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988; 319:80-6. http://www.ncbi.nlm.nih.gov/pubmed/2967917?dopt=AbstractPlus

293. Ambrosioni E, Borghi C, Magnani B for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995; 332:80-5. http://www.ncbi.nlm.nih.gov/pubmed/7990904?dopt=AbstractPlus

294. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342:821-8. http://www.ncbi.nlm.nih.gov/pubmed/8104270?dopt=AbstractPlus

295. Ball SG, Hall AS, Murray GD. Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing J Am Coll Cardiol. 1995; 25(Suppl):42-6S. (IDIS 350026)

296. ISIS-4 Collaborative Group. Fourth international study of infarct survival: protocol for a large simple study of the effects of oral mononitrate, of oral captopril, and intravenous magnesium. Am J Cardiol. 1991; 68:87-100D.

297. Simoons ML. Myocardial infarction: ACE inhibitors for all? for ever? Lancet. 1994; 344:279-81. Editorial.

298. Anon. An ACE inhibitor after a myocardial infarction. Med Lett Drugs Ther. 1994; 36:69-70. http://www.ncbi.nlm.nih.gov/pubmed/8035753?dopt=AbstractPlus

299. Ertl G, Jugdutt B. ACE inhibition after myocardial infarction: can megatrials provide answers? Lancet. 1994; 344:1068-9.

300. Ertl G. Angiotensin converting enzyme inhibitors in angina and myocardial infarction: what role will they play in the 1990s? Drugs. 1993; 46:209-18.

301. Purcell H, Coats A, Fox K et al. Improving outcome after acute myocardial infarction: what is the role of ACE inhibitors? Br J Clin Pract. 1995; 49:195-9. (IDIS 349780)

302. Ball SG, Hall AS. What to expect from ACE inhibitors after myocardial infarction. Br Heart J. 1994; 72(Suppl):S70-4.

303. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet. 1995; 345:669-85. http://www.ncbi.nlm.nih.gov/pubmed/7661937?dopt=AbstractPlus

304. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet. 1995; 345:686-7. http://www.ncbi.nlm.nih.gov/pubmed/7885123?dopt=AbstractPlus

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. http://www.ncbi.nlm.nih.gov/pubmed/24352797?dopt=AbstractPlus

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. http://www.ncbi.nlm.nih.gov/pubmed/23817082?dopt=AbstractPlus

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85. http://www.ncbi.nlm.nih.gov/pubmed/24243703?dopt=AbstractPlus

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26. http://www.ncbi.nlm.nih.gov/pubmed/24341872?dopt=AbstractPlus

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503. http://www.ncbi.nlm.nih.gov/pubmed/24424788?dopt=AbstractPlus

506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4. http://www.ncbi.nlm.nih.gov/pubmed/24549531?dopt=AbstractPlus

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6. http://www.ncbi.nlm.nih.gov/pubmed/24352710?dopt=AbstractPlus

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8. http://www.ncbi.nlm.nih.gov/pubmed/24352759?dopt=AbstractPlus

511. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008; 31:2115-27. http://www.ncbi.nlm.nih.gov/pubmed/19139601?dopt=AbstractPlus

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88. http://www.ncbi.nlm.nih.gov/pubmed/24591473?dopt=AbstractPlus

520. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014; 37 Suppl 1:S14-80.

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.

525. Smith SC, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124:2458-73. http://www.ncbi.nlm.nih.gov/pubmed/22052934?dopt=AbstractPlus

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :. http://www.ncbi.nlm.nih.gov/pubmed/24788967?dopt=AbstractPlus

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3695607&blobtype=pdf

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8. http://www.ncbi.nlm.nih.gov/pubmed/24641124?dopt=AbstractPlus

534. Qaseem A, Hopkins RH, Sweet DE et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013; 159:835-47. http://www.ncbi.nlm.nih.gov/pubmed/24145991?dopt=AbstractPlus

535. Taler SJ, Agarwal R, Bakris GL et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013; 62:201-13. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3929429&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/23684145?dopt=AbstractPlus

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012: 2: 337-414.

541. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33:1635-701. http://www.ncbi.nlm.nih.gov/pubmed/22555213?dopt=AbstractPlus

543. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease (2002). From National Kidney Foundation website. http://www.kidney.org/professionals/kdoqi/guidelines_commentaries.cfm

550. US Food and Drug Administration. FDA Drug Safety Communication: new warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). Rockville, MD; 2012 April 4. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm

600. Merck. Prinivil (lisinopril) tablets prescribing information. Whitehouse Station, NJ; 2012 Dec.

700. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; 134:e282-93.

701. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37:2129-200. http://www.ncbi.nlm.nih.gov/pubmed/27206819?dopt=AbstractPlus

702. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371:993-1004. http://www.ncbi.nlm.nih.gov/pubmed/25176015?dopt=AbstractPlus

703. Ansara AJ, Kolanczyk DM, Koehler JM. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. J Clin Pharm Ther. 2016; 41:119-27. http://www.ncbi.nlm.nih.gov/pubmed/26992459?dopt=AbstractPlus

803. Lamas GA, Escolar E, Faxon DP. Examining treatment of ST-elevation myocardial infarction: the importance of early intervention. J Cardiovasc Pharmacol Ther. 2010; 15:6-16. http://www.ncbi.nlm.nih.gov/pubmed/20061507?dopt=AbstractPlus

805. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017; 389:197-210. http://www.ncbi.nlm.nih.gov/pubmed/27502078?dopt=AbstractPlus

1100. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:e344-426. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4676081&blobtype=pdf

1150. Flynn JT, Kaelber DC, Baker-Smith CM et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017; 140 http://www.ncbi.nlm.nih.gov/pubmed/28827377?dopt=AbstractPlus

1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:el13-e115. http://www.ncbi.nlm.nih.gov/pubmed/29133356?dopt=AbstractPlus

1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med. 2018; 378:497-499. http://www.ncbi.nlm.nih.gov/pubmed/29341841?dopt=AbstractPlus

1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168:351-358. http://www.ncbi.nlm.nih.gov/pubmed/29357392?dopt=AbstractPlus

1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Press. 2018; 27:62-65. http://www.ncbi.nlm.nih.gov/pubmed/29447001?dopt=AbstractPlus

1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166:430-437. http://www.ncbi.nlm.nih.gov/pubmed/28135725?dopt=AbstractPlus

1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=AbstractPlus

1213. Reboussin DM, Allen NB, Griswold ME et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71:2176-2198. http://www.ncbi.nlm.nih.gov/pubmed/29146534?dopt=AbstractPlus

1214. American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes 2018. Diabetes Care. 2018; 41:S86-S104. http://www.ncbi.nlm.nih.gov/pubmed/29222380?dopt=AbstractPlus

1215. de Boer IH, Bangalore S, Benetos A et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017; 40:1273-1284. http://www.ncbi.nlm.nih.gov/pubmed/28830958?dopt=AbstractPlus

1216. Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018; 378:636-644. http://www.ncbi.nlm.nih.gov/pubmed/29443671?dopt=AbstractPlus

1218. Messerli FH, Bangalore S, Bavishi C et al. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?. J Am Coll Cardiol. 2018; 71:1474-1482. http://www.ncbi.nlm.nih.gov/pubmed/29598869?dopt=AbstractPlus

1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA. 2017; 318:2132-2134. http://www.ncbi.nlm.nih.gov/pubmed/29159416?dopt=AbstractPlus

1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med. 2018; 178:755-7. http://www.ncbi.nlm.nih.gov/pubmed/29710197?dopt=AbstractPlus

1223. LeFevre M. ACC/AHA hypertension guideline: what is new? what do we do?. Am Fam Physician. 2018; 97(6):372-3. http://www.ncbi.nlm.nih.gov/pubmed/29671534?dopt=AbstractPlus

1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. https://www.jwatch.org/na45778/2017/12/28/nejm-journal-watch-general-medicine-year-review-2017

1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2018; 319(2):115-6. http://www.ncbi.nlm.nih.gov/pubmed/29242891?dopt=AbstractPlus

1232. American Diabetes Association. 10. Microvascular complications and foot care: standards of medical care in diabetes 2018. Diabetes Care. 2018; 41:S86-S104. http://www.ncbi.nlm.nih.gov/pubmed/29222381?dopt=AbstractPlus

Frequently asked questions

View more FAQ

Medical Disclaimer